Biliary atresia (BA) is a severe pediatric liver disease resulting in necroinflammatory obliteration of the extrahepatic biliary tree. BA presents within the first few months of life as either an isolated finding or with additional syndromic features. The etiology of isolated BA is unknown, with evidence for infectious, environmental, and genetic risk factors described. However, to date, there are no definitive causal genes identified for isolated BA in humans, and the question of whether single gene defects play a major role remains open. We performed exome-sequencing in 100 North American patients of European descent with isolated BA (including 30 parent-child trios) and considered several experimental designs to identify potentially deleterious protein-altering variants that may be involved in the disease. In a case-only analysis, we did not identify genes with variants shared among more than two probands, and burden tests of rare variants using a case-case control design did not yield significant results. In the trio analysis of 30 simplex families (patient and parent trios), we identified 66 de novo variants in 66 genes including a nonsense variant, p.(Cys30Ter), in the gene STIP1. STIP1 is a co-chaperone for the heat-shock protein, HSP90AA1, and has been shown to be a modifier of a biliary phenotype in zebrafish exposed to a known BA-associated toxin (biliatresone).
Introduction
Biliary atresia (BA) is an obstructive cholangiopathy with initial symptoms arising during the first days to weeks of life. BA occurs as an isolated finding in 85% of affected individuals, and with additional syndromic features (heterotaxy and/or other congenital birth defects) in 15% 1 . The incidence of BA varies across different populations, with estimates ranging from 1 in 5,000 to 1 in 14,000 live births 2 . BA presents clinically with neonatal cholestasis, elevated bilirubin and liver enzymes, although the differential diagnosis suggested by these findings is extensive. The diagnosis of BA is suggested by features of biliary obstruction on liver histology, including bile duct proliferation, portal tract expansion and bile plugs. The diagnosis is confirmed upon intraoperative cholangiogram showing lack of patency of the extrahepatic biliary tree.
Although the etiology of BA is not clear, a genetic component is supported by multiple lines of evidence. These include the presence of familial cases [3] [4] [5] , case reports of individuals with syndromic BA with likely causal genes identified (including FOXA2 6 , CFC1 7,8 , ZEB2 9 , ZIC3 10 , HNF1B 11 and PKD1L1 12 ), animal models of BA involving the genes Sox17 13 , Foxm1 14 , Invs 15 , Onecut1 16 , and candidate susceptibility genes including ADD3 17 , GPC1 18 , EFEMP1 19 and ARF6 20 identified by genome-wide association studies (GWAS). Genes implicated in syndromic BA function in bile-duct development and the establishment of left-right symmetry. A follow-up study of GPC1 using a zebrafish model confirmed that suppressing GPC1 expression gives rise to biliary defects 21 . A GWAS identified SNPs associated with BA upstream of XPNPEP1 and ADD3 in a Chinese cohort of isolated BA patients 17 , and this association has been confirmed in both a Thai 22 and an European-American cohort 23 . In a study of 499 isolated and syndromic BA patients and 1928 controls, our group identified a GWAS signal within 2p16.1 implicating common variants in the gene EFEMP1 19 . Another genome-wide association study of 63 BA patients and 1907 controls identified two SNPs downstream of the gene ARF6 associated with isolated BA 20 , although we could not replicate this finding in our study. However, to date, no genes have been definitively identified as a cause of isolated BA. Environmental exposure to virus or toxins has long been proposed as a hypothesis for perinatal form of BA 2 . But the genetic susceptibility factors linking such exposure and BA are yet to be identified.
In this work, we hypothesized that rare and novel, deleterious, protein-altering variants transmitted in a Mendelian fashion are involved in the etiology of isolated BA, and patients with isolated BA are likely to be enriched with such variants. To test this hypothesis, we considered three experimental designs ( Table 1) . First, we conducted a case-only analysis where we looked for potentially deleterious novel variants. In the second design, we conducted a case-control analysis comparing the cumulative frequency of rare variants in the two groups. Finally, we performed trio analysis on a subset of 30 probands to identify genes with rare, protein-altering de novo and compound heterozygous or homozygous variants.
Patients and Methods

Patients with isolated BA and controls
We studied a cohort of 100 self-reported white, non-Hispanic patients with isolated BA.
The 100 patients were chosen from a larger cohort of 1063 BA cases based on their selfreported race and ethnicity and availability of parental DNA samples. Ninety-nine participants were enrolled in the NIDDK-funded Childhood Liver Disease Research Network (ChiLDReN) at one of the sixteen participating institutions under Institutional Review Board (IRB) approved protocols (IRB 04-003655 and 06-004814). A set of dizygotic twins were consented into the approved IRB study at the Children's Memorial Hospital, Chicago, IL and only one of them were part of the cohort as the scope of the current work was to analyze unrelated individuals. Informed consent in wirting was obtained from each patient enrolled in this study. The diagnosis of BA was made by clinical presentation, liver histology, and an intraoperative cholangiogram. Most patients also had BA confirmed by examination of the biliary remnant from a Roux-en-Y hepatic portoenterostomy (also known as a Kasai operation). DNA samples were extracted from whole blood or lymphoblastoid cell lines. For a subset of patients (n = 30), DNA samples were available from both parents.
Controls were individuals recruited from two different studies at the Children's Hospital of Philadelphia, PediSeq (the CHOP cohort of the Clinical Sequencing and Exploratory Research (CSER) consortium 24 , and VEO-IBD (Very-Early Onset Inflammatory Bowel Disease) 25 , and enrolled in institution-approved IRB protocols (IRB 12-009169; 14-010826). Controls from the PediSeq dataset (n=158) fall into four different disease cohorts (cardiovascular, hearing loss, mitochondrial and intellectual disability) but have no known liver disease. Controls from the VEO-IBD cohort (n=145) were the unaffected parents of individuals with VEO-IBD. The patient recruitment, methods, and experimental protocols used in these studies were performed in accordance with relevant guidelines and regulations set by the aforementioned institutions. This study was approved by the ethics committee at the Children's Hospital of Philadelphia.
Exome sequencing (ES)
Genomic DNA (3-5 ug All of the exome sequencing data was produced with paired-end reads of 100 base-pairs in length (2 x 100bp). The unaligned FASTQ reads of all samples were returned to us for read analysis and downstream processing as detailed below.
Variant calling and annotation
Raw sequencing reads were mapped to the GRCh37.69 reference genome using the Burrows-Wheeler Aligner 26 to produce an aligned BAM file. BAM files were realigned around known indels using IndelRealigner in the GenomeAnalysisToolKit software (GATK) and base quality scores were recalibrated using the BaseQualityScoreRecalibrator in GATK 27 . Variant calling was performed using
HaplotypeCaller and jointly genotyped using the GenotypeGVCFs command in GATK.
The initial variant quality filtering was done using the VariantQualityScoreRecalibrator (VQSR) in GATK. SNPEff 28 was used to annotate the variants with their expected functional consequence. Other annotations such as allele frequencies in non-Finnish Europeans (NFE) from the gnomAD variant database, and deleteriousness scores such as CADD (Combined Annotation Dependent Depletion version 1.4) 29 were added using the Gemini software 30 . We manually reviewed all variants found in the de novo analysis, and variant clusters with overlapping genomic positions that could be indicative of technical artifacts 31 .
Population stratification, relatedness and sex check
The Peddy 32 software tool was used to infer genetic ancestry from the exome sequencing data by comparing our samples against the samples from the 1000 Genomes Project Phase 3 33 . All samples from BA patients and their parents clustered with the European populations in the 1000 Genomes Project. We also confirmed the sex of the participants based on heterozygosity of X chromosome variants. Pairwise relatedness (estimated by the kinship coefficient) between samples was investigated using the KING 34 software and confirmed that there were no related individuals in the entire cohort beside the known parent-child pairs used in the trio analysis.
Variant prioritization
We filtered the variants identified from the ES for stop gain, stop loss, frameshift and inframe insertions/deletions (InDels), missense and splicing variants. We excluded variants overlapping with segmental duplications and variants with call rate less than 90% from all analyses. In the case-only analysis, we included novel and potentially deleterious variants, defined as variants that were not present in the Non-Finnish European (NFE) population of the gnomAD genomes and exomes and had a phred-scaled CADD score of at least 30, representing the top 0.1% of the potentially deterious variants. For the burden tests in the case-control experimental design, all protein-altering variants with a cohort (cases and controls combined) minor allele frequency (MAF) of <5% were included. We did not apply a CADD score threshold for this analysis. For the de novo analysis, we considered all variants irrespective of their frequency or the CADD score. For the analysis under the recessive model, we retained variants with an allele frequency in gnomAD NFE less than or equal to 0.1% and a CADD score of at least 30. Details pertaining to variant prioritization are provided in Table 1 .
Autosomal copy-number variant (CNV) analysis
Mean depth of coverage for each individual exonic interval in the autosomes was computed using the DepthOfCoverage routine in the GATK package and copy number variants were called using XHMM following the protocol described elsewhere 35 . We excluded CNVs with quality score (Q_SOME) less than 60 to retain only high quality CNVs. To identify novel CNVs, we excluded any variant found in the Database of Genomic Variants (DGV) 36 and the ExAC 37 . We did not look for CNVs in the sex chromosomes as the ExAC dataset only had calls from autosomes.
Gene, pathway and gene-set definitions
For all the analyses, we used refFlat_hg19 gene definitions from the UCSC genome browser 38 . We used pathway definitions including KEGG (n = 293), Panther (n = 112), Reactome (n = 1530), WikiPathways (n = 437) and BioCarta (n = 237), and annotation gene-sets from Gene Ontology (GO) Biological Process (n = 5192), Molecular Functions (n = 1136) and Cellular Components (n=641) downloaded from the Enrichr website 39 .
Case-only and trio analyses: Over representation tests
To determine if our lists of candidate genes from the case-only and trio analyses were enriched for specific gene-sets or pathways, we performed over-representation analysis using the R package enrichR 39 . This software essentially counts the number of genes with a given annotation that are present in our lists of candidate genes and genome-wide, and compares it to the number of genes that are not associated with the same annotation in our lists and genome-wide, using a Fisher exact test. Over representation tests were carried out on gene-sets and pathways.
Case-control analysis: Rare variant burden tests
To test if a gene, gene-set or pathway contained significantly more cases with at least one rare variant (MAF < 5%) compared to controls, we performed burden tests using the Combined and Multivariate Collapsing (CMC) approach 40 implemented in the exactCMC procedure from the software package rvtests 41 . Burden tests were carried out at different levels including 1) the gene level; 2) the gene-set level (e.g. collection of genes with similar function or structure or cellular localization, such as sodium channel genes or membrane bound receptors); and 3) the pathway level, which includes genes that function in a specific biological pathway (e.g. WNT or NOTCH signaling). The number of cases and controls with and without at least one rare variant in a given gene, gene-set, or pathway were compared using a Fisher exact test.
Trio analysis
Trio analysis was performed using Gemini software 30 in a subset of 30 probands for whom DNA from both parents was available for ES. De novo variants were identified using the command `de_novo` which essentially identifies SNVs and indels occuring in proband only and not in the parents. Further, we filtered for exonic, protein-altering and splice-site variants. Compound heterozygous variants were identified using the command `comp_het` which identifies two heterozygous variants in the same gene inherited from different parents. Homozygous variants were identified using the `autosomal_recessive` command which identifies rare variants transmitted to the proband from both parents.
To test if the total number of de novo protein-altering (missense and loss-of-function) variants identified in our cohort was significantly larger than expected, we used the Rpackage denovolyzeR 42 . The denovolyzeByClass function implemented in the denovolyzeR package computes the significance of the observed number of exonic variants compared to the pre-computed de novo mutation rates for all classes of exonic variants.
Statistical significance
For gene level burden tests, the raw p-values were corrected for multiple testing using a
Bonferroni correction for the total number of genes tested (n=16,393). For the pathway based analyses, the raw P-values were corrected for multiple testing using a Bonferroni correction for the total number of pathway definitions (n=2609). For the gene-set based analyses, we corrected for the total number of gene-sets used in the analysis (n = 6969).
We considered a test to be statistically significant if the Bonferroni-adjusted p-value was less than or equal to 0.05.
Results
Case-only analysis
In the case-only analysis we identified a total of 496,654 potentially deleterious novel variants in the 100 probands. These included variants that passed the quality filters, of Table 1 .
Case-control analysis
In the second experimental design, we conducted burden tests for rare variants (MAF < 5%) by comparing their cumulative number in a gene, gene-set or pathway in the 100 cases against the 303 controls. After correcting for the multiple testing, we did not identify any gene, gene-set or a pathway with a statistically significant excess of rare variants in the cases compared to the controls.
Trio analysis
In the final experimental design, we sequenced the parents of a subset of the patients (n = 30) to identify de novo variants in the probands under the hypothesis that they are more likely to be involved in the etiology of the disease. We identified a total of 66 de novo, protein-altering and splice variants in 66 different genes in 25 out of 30 individuals, with a mean of 2.2 variants per individual (range: 0-7; median 3). We did not identify any de novo variants in five individuals. All the de novo variants were manually verified in the BAM file and a small subset of them were validated using Sanger sequencing (n = 4).
There were 58 missense, 3 frameshift indels, 3 nonsense, and 2 splice-site variants. A prioritized list of 14 de novo variants are provided in Table 2 and the list of all de novo variants are provided in the Supp. Table 2 Over-representation analysis of the 66 genes did not yield significant results after correcting for multiple testing. We did not identify any compound heterozygous or homozygous variants at a maximum alternate allele frequency threshold of 0.1% and a phred-scaled CADD score of 30.
Discussion
In this study, exome sequencing was used to identify genomic changes in a cohort of patients with isolated biliary atresia, and in spite of the utilization of several distinct strategies, we were unable to demonstrate an associated genetic change. We did identify a candidate gene by analysis of 30 trios, finding a de novo likely pathogenic variant in STIP1, which we hypothesize may result in susceptibility to toxin induced biliary disease.
BA presents as an isolated finding in 85% of cases, and in a syndromic form with laterality and/or other congenital malformations in 15%. Mouse models of BA (Sox17, However, the genetic susceptibility factors that might link exposure to these agents and biliary atresia are yet to be identified. In summary, from previous literature, there are genes that are known to cause syndromic forms of BA in humans and mice, genes that are associated with isolated BA identified via GWAS, and biological pathways that are perturbed in zebrafish treated with the toxin Biliatresone, which has been associated with biliary atresia in sheep. However, in spite of these clues, there has not been a causal gene identified for isolated BA in humans.
In this work, we performed exome sequencing in 100 North American unrelated patients of European ancestry with isolated BA and looked for novel or rare protein-altering variants that may explain the BA phenotype (strategies presented in Table 1 ). Such study designs have been successful in finding novel genes responsible for rare Mendelian diseases 45 . Fewer exome sequencing studies with sufficiently large sample sizes have been successfully employed in identifying associations with complex phenotypes 46, 47 .
This study was primarily designed with the goal of finding genes with rare and highly deleterious variants that may explain the occurrence of isolated BA. We considered three experimental designs including a case-only analysis to look for novel, potentially deleterious and protein-altering variants, a case-control analysis to look for an excessive burden of rare variants in the cases compared to the controls, and a trio analysis, to look for de novo and homozygous or compound heterozygous variants.
In the case-only design, we identified 332 novel and potentially deleterious proteinaltering variants in our cohort of 100 individuals with isolated BA. The majority of the variants were found in a single individual in a heterozygous state. Six genes had variants in two individuals, and the variants were different from each other. This suggests that BA is unlikely to result from a single genetic change, although we cannot rule out extreme locus heterogeneity, with a small percentage of cases having a genetic etiology, perhaps in combination with an environmental insult. Case-control analysis did not yield any statistically significant result and this may suggest that there are no variants or genes with large enough effect sizes present in the cases as compared to the controls or simply the sample size is too small to identify such a difference between cases and controls.
Trio-based exome sequence analysis identified 66 de novo protein-altering variants in 66 genes in 25 out of 30 patients, a number significantly higher than expected (p-value = 4.15x10 -13 ). All putative loss-of-function de novo variants and a prioritized list of de novo missense variants with a CADD score greater than or equal to 30 are provided in Table 2 .
Of all the genes with putative loss-of-function de novo variants, a splice-acceptor variant in the gene REV1 and a premature stop in one of the transcripts in the gene STIP1 were the most interesting for several reasons. These genes seem to be intolerant for loss-offunction variants with a perfect pLI score of 1. STIP1 is a chaperone that assists in the transfer of proteins from HSP70 to HSP90, which are an integral part of the heat shock response pathway and as mentioned below, HSP90 down-regulation has been implicated in BA livers. Mass spectrometry experiments to identify differentially expressed proteins in 20 BA liver biopsies compared to 12 non-BA, neonatal cholestasis livers found that heat shock protein 90 (HSP90) was significantly down-regulated in BA livers, and was the most significantly altered protein. This suggests that HSP90 could serve as a potential biomarker for BA 48 . We therefore hypothesized that a gene-environment interaction may explain isolated BA where a predisposing genetic factor exists and an external insult triggers the initiation of the disease. Based on the de novo variant found in the human exome data, the identification of the heatshock response pathway as differentially expressed in zebrafish, our collaborators performed a CRISPR/Cas9 based experiment to introduce a frameshift mutation in exon 1 of the zebrafish stip1 gene to create heterozygous mutant fish. When treated with toxin, stip1 heterozygous fish were highly sensitive to a low dose of biliatresone compared to the wild-type 49 . REV1 encodes a protein similar to the S. cerevisiae mutagenesis protein Rev1 and is known to be involved in DNA repair. REV1 is shown to be regulated by the heat-shock protein HSP90
in the DNA repair pathway 50 and further functional studies are warranted to understand its role in BA.
Our study has several limitations including sample size (which is a function of the disease frequency) and the failure of exome sequencing to identify all possible disease causing genomic changes. The sample size was relatively small for statistical analyses such as rare variant burden tests and for the trio analysis whose aim was to identify genes with recurring de novo variants. Exome sequencing is a targeted capture experiment which focuses only on the exonic regions, and coverage might not be uniform through the coding parts of the genome. This limits our ability to study intronic regions and/or poorly targeted parts of the genome. Copy-number detection from exome sequencing is challenging and XHMM software tool used in this work is tuned for specificity rather than sensitivity. Finally, exome sequencing does not allow us to look for structural variation in these samples.
Together, our analysis of rare and novel coding variants does not support a simple genetic model in which a small number of genes are responsible for the majority of cases with isolated BA. However, the identification of a loss-of-function de novo variant in the gene STIP1 and the existing evidence for its sensitivity to the biliatresone toxin in zebrafish opened new opportunities for further investigating BA as a consequence of environmental exposure. Potentially, other genes in the heat shock response pathway or other pathways identified in the zebrafish experiments could be considered as candidates. TR000130, TR001872, TR001857, TR001108, TR002535, TR000454, TR000423,   RR025014, TR000077 and TR000003 .
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